A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer
{{output}}
Purpose: Early identification of response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytical and clinical validity study (TNPET01) eval... ...
